Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy

Aim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: Cultured Hep-2 cells were treated with 0.25, 2...

Full description

Saved in:
Bibliographic Details
Published in:Experimental Oncology
Date:2012
Main Authors: Galbiatti, A.L.S., Caldas, H.C., Padovani Junior, J.A., Pavarino, E.C., Goloni-Bertollo, E.M.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2012
Subjects:
Online Access:https://nasplib.isofts.kiev.ua/handle/123456789/139856
Tags: Add Tag
No Tags, Be the first to tag this record!
Journal Title:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Cite this:Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy / A.L.S. Galbiatti, H.C. Caldas, J.A. Padovani Junior, E.C. Pavarino, E.M. Goloni-Bertollo // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 367-369. — Бібліогр.: 22 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-139856
record_format dspace
spelling Galbiatti, A.L.S.
Caldas, H.C.
Padovani Junior, J.A.
Pavarino, E.C.
Goloni-Bertollo, E.M.
2018-06-21T12:37:44Z
2018-06-21T12:37:44Z
2012
Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy / A.L.S. Galbiatti, H.C. Caldas, J.A. Padovani Junior, E.C. Pavarino, E.M. Goloni-Bertollo // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 367-369. — Бібліогр.: 22 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/139856
Aim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 μM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC antibody in flow cytometry. Results: The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability of Hep-2 cells in vitro. Conclusion: The highest MTX concentration is associated with highest tumor cell sensitivity of human laryngeal cancer cells of Hep-2 line.
Fundação de Amparo а Pesquisa do Estado de Sгo Paulo (FAPESP) for their financial support (Nє 2010/12930-4, 2010/12932-7); Prof. Dr. Moacir F. Godoy for their help in statistical analysis; Profa. Dra Eloiza Helena Tajara for providing of the cell line; Oncology Department, Hospital de Base, São José do Rio Preto for providing of the Methotrexate Chemotherapeutic; CNPQ (National Counsel of Technological and Scientific Development) and FAMERP/FUNFARME.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Short communications
Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
spellingShingle Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
Galbiatti, A.L.S.
Caldas, H.C.
Padovani Junior, J.A.
Pavarino, E.C.
Goloni-Bertollo, E.M.
Short communications
title_short Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
title_full Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
title_fullStr Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
title_full_unstemmed Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
title_sort sensitivity of human laryngeal squamous cell carcinoma hep-2 to metrotexate chemoterapy
author Galbiatti, A.L.S.
Caldas, H.C.
Padovani Junior, J.A.
Pavarino, E.C.
Goloni-Bertollo, E.M.
author_facet Galbiatti, A.L.S.
Caldas, H.C.
Padovani Junior, J.A.
Pavarino, E.C.
Goloni-Bertollo, E.M.
topic Short communications
topic_facet Short communications
publishDate 2012
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Aim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 μM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC antibody in flow cytometry. Results: The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability of Hep-2 cells in vitro. Conclusion: The highest MTX concentration is associated with highest tumor cell sensitivity of human laryngeal cancer cells of Hep-2 line.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/139856
citation_txt Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy / A.L.S. Galbiatti, H.C. Caldas, J.A. Padovani Junior, E.C. Pavarino, E.M. Goloni-Bertollo // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 367-369. — Бібліогр.: 22 назв. — англ.
work_keys_str_mv AT galbiattials sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy
AT caldashc sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy
AT padovanijuniorja sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy
AT pavarinoec sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy
AT golonibertolloem sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy
first_indexed 2025-12-07T19:56:35Z
last_indexed 2025-12-07T19:56:35Z
_version_ 1850880709673091072